Effect of perioperative levosimendan administration on postoperative N- terminal pro-B-type natriuretic peptide concentration in patients with increased cardiovascular risk factors undergoing non-cardiac surgery: protocol for the double-blind, randomised, placebo- controlled IMPROVE trial

被引:2
作者
Reiterer, Christian [1 ]
Kabon, Barbara [2 ]
Taschner, Alexander [2 ]
Adamowitsch, Nikolas [2 ]
Graf, Alexandra [3 ]
Fraunschiel, Melanie [4 ]
Horvath, Katharina [2 ]
Kuhrn, Melanie [2 ]
Clement, Theresa [2 ]
Treskatsch, Sascha [5 ]
Berger, Christian [5 ]
Fleischmann, Edith [1 ,2 ]
机构
[1] Outcome Res Consortium, Dept Anesthesia Intens Care Med & Pain Med, Cleveland, OH USA
[2] Med Univ Vienna, Dept Anaesthesia Intens Care Med & Pain Med, Vienna, Austria
[3] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria
[4] Med Univ Vienna, ITSC IT Syst & Commun, Vienna, Austria
[5] Charite Univ Med Berlin, Dept Anesthesiol & Intens Care Med, Berlin, Germany
来源
BMJ OPEN | 2022年 / 12卷 / 01期
关键词
MYOCARDIAL INJURY; HEART-FAILURE; BYPASS; INFUSION;
D O I
10.1136/bmjopen-2021-058216
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Elevated N-terminal pro-brain natriuretic peptide (NT-pro-BNP) after non-cardiac surgery is a strong predictor for cardiovascular complications and reflects increased myocardial strain. NT-pro-BNP concentrations significantly rise after non-cardiac surgery within the first 3 days. Levosimendan is a potent inotropic drug that increases calcium sensitivity to cardiac myocytes, which results in improved cardiac contractility that last for approximately 7 days. Thus, we will test the effect of a pre-emptive perioperative administration of levosimendan on postoperative NT-pro-BNP concentration as compared with the administration of a placebo in patients undergoing moderate-risk to high-risk major abdominal surgery. Methods and analysis We will conduct a double-blinded prospective randomised trial at the Medical University of Vienna, Vienna, Austria (and potentially a second centre in Germany), including 230 patients at-risk for cardiovascular complications undergoing moderate- to high-risk major abdominal surgery. Patients will be randomly assigned to receive a single dose of 12.5 mg levosimendan versus placebo after induction of anaesthesia. The primary outcome will be the postoperative maximum NT-pro-BNP concentration between both group within the first three postoperative days. Our secondary outcomes will be the incidence of myocardial ischaemia, myocardial injury after non-cardiac surgery and a composite of myocardial infarction and death within 30 days and 1 year after surgery between both groups. Our further secondary outcome will be stratification of NT-pro-BNP values according to previously thresholds to predict mortality of myocardial infarction after surgery. Ethics and dissemination The study was approved by the Ethics Committee of the Medical University of Vienna on 14 July 2020 (EK 2187/2019). Written informed consent will be obtained from all patients a day before surgery. Results of this study will be submitted for publication in a peer-reviewed journal.
引用
收藏
页数:11
相关论文
共 22 条
  • [1] Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance
    Abassi, Z
    Karram, T
    Ellaham, S
    Winaver, J
    Hoffman, A
    [J]. PHARMACOLOGY & THERAPEUTICS, 2004, 102 (03) : 223 - 241
  • [2] Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass The LICORN Randomized Clinical Trial
    Cholley, Bernard
    Caruba, Thibaut
    Grosjean, Sandrine
    Amour, Julien
    Ouattara, Alexandre
    Villacorta, Judith
    Miguet, Bertrand
    Guinet, Patrick
    Levy, FranOois
    Squara, Pierre
    Hamou, Nora Ait
    Carillon, Aude
    Boyer, Julie
    Boughenou, Marie-Fazia
    Rosier, Sebastien
    Robin, Emmanuel
    Radutoiu, Mihail
    Durand, Michel
    Guidon, Catherine
    Desebbe, Olivier
    Charles-Nelson, Anais
    Menasche, Philippe
    Rozec, Bertrand
    Girard, Claude
    Fellahi, Jean-Luc
    Pirracchio, Romain
    Chatellier, Gilles
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (06): : 548 - 556
  • [3] Myocardial injury after non-cardiac surgery: diagnosis and management
    Devereaux, P. J.
    Szczeklik, Wojciech
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 (32) : 3083 - 3091
  • [4] Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery
    Devereaux, P. J.
    Biccard, Bruce M.
    Sigamani, Alben
    Xavier, Denis
    Chan, Matthew T. V.
    Srinathan, Sadeesh K.
    Walsh, Michael
    Abraham, Valsa
    Pearse, Rupert
    Wang, C. Y.
    Sessler, Daniel I.
    Kurz, Andrea
    Szczeklik, Wojciech
    Berwanger, Otavio
    Carlos Villar, Juan
    Malaga, German
    Garg, Amit X.
    Chow, Clara K.
    Ackland, Gareth
    Patel, Ameen
    Borges, Flavia Kessler
    Belley-Cote, Emilie P.
    Duceppe, Emmanuelle
    Spence, Jessica
    Tandon, Vikas
    Williams, Colin
    Sapsford, Robert J.
    Polanczyk, Carisi A.
    Tiboni, Maria
    Alonso-Coello, Pablo
    Faruqui, Atiya
    Heels-Ansdell, Diane
    Lamy, Andre
    Whitlock, Richard
    LeManach, Yannick
    Roshanov, Pavel S.
    McGillion, Michael
    Kavsak, Peter
    McQueen, Matthew J.
    Thabane, Lehana
    Rodseth, Reitze N.
    Buse, Giovanna A. Lurati
    Bhandari, Mohit
    Garutti, Ignacia
    Jacka, Michael J.
    Schuenemann, Holger J.
    Lucia Cortes, Olga
    Coriat, Pierre
    Dvirnik, Nazari
    Botto, Fernando
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (16): : 1642 - 1651
  • [5] Development and Feasibility Study of an Algorithm for Intraoperative Goal-directed Haemodynamic Management in Noncardiac Surgery
    Feldheiser, A.
    Conroy, P.
    Bonomo, T.
    Cox, B.
    Ruiz Garces, T.
    Spies, C.
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2012, 40 (04) : 1227 - 1241
  • [6] Goal-directed intraoperative fluid administration reduces length of hospital stay after major surgery
    Gan, TJ
    Soppitt, A
    Maroof, M
    El-Moalem, H
    Robertson, KM
    Moretti, E
    Dwane, P
    Glass, PSA
    [J]. ANESTHESIOLOGY, 2002, 97 (04) : 820 - 826
  • [7] Kivikko M, 2002, INT J CLIN PHARM TH, V40, P465
  • [8] Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting
    Lilleberg, J
    Nieminen, MS
    Akkila, J
    Heikkila, L
    Kuitunen, A
    Lehtonen, L
    Verkkala, K
    Mattila, S
    Salmenpera, M
    [J]. EUROPEAN HEART JOURNAL, 1998, 19 (04) : 660 - 668
  • [9] Levosimendan vs dobutamine for patients with acute decompensated heart failure - The SURVIVE randomized trial
    Mebazaa, Alexandre
    Nieminen, Markku S.
    Packer, Milton
    Cohen-Solal, Alain
    Kleber, Franz X.
    Pocock, Stuart J.
    Thakkar, Roopal
    Padley, Robert J.
    Poder, Pentti
    Kivikko, Matti
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (17): : 1883 - 1891
  • [10] Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery
    Mehta, R. H.
    Leimberger, J. D.
    van Diepen, S.
    Meza, J.
    Wang, A.
    Jankowich, R.
    Harrison, R. W.
    Hay, D.
    Fremes, S.
    Duncan, A.
    Soltesz, E. G.
    Luber, J.
    Park, S.
    Argenziano, M.
    Murphy, E.
    Marcel, R.
    Kalavrouziotis, D.
    Nagpal, D.
    Bozinovski, J.
    Toller, W.
    Heringlake, M.
    Goodman, S. G.
    Levy, J. H.
    Harrington, R. A.
    Anstrom, K. J.
    Alexander, J. H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (21) : 2032 - 2042